Radicicol

Hsp90 inhibitor

Product Specifications

Background

Radicicol inhibits src (IC50=0.27µM) and src-like kinases(1), leading to hypophosphorylation of retinoblastoma tumor suppressor protein(2). It causes morphological reversion of ras-transformed cells(3) and leads to selective depletion of Raf kinase(4). It also displays anti-angiogenic activity(5), and binds to and inhibits Hsp 90 molecular chaperone(6). It binds more strongly to Hsp90 than to GRP94. It also binds to yeast HSP90, E. coli HtpG and TRAP-1. Looking for more information on HSP90? Visit our new HSP90 Scientific Resource Guide at http://www.HSP90.ca.

CAS Number

12772-57-5

UNSPSC

41116105

Type

Inhibitor

Source

Produced by fermentation

Field of Research

Cancer | Heat Shock

Purity

97% by TLC

Weight

0.001

Format

White to Yellow Solid

Solubility

Soluble in DMSO

Molecular Formula

C18H17CIO6

Molecular Weight

364.8

Precautions

Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.

References & Citations

1. Kwon H.J., et al. (1992) Cancer Res. 52: 6929. 2. Yen A., et al. (1994) Exp.Cell Res. 214: 163. 3. Kwon H.J., et al. (1995) J.Biochem.(Tokyo) 118: 221. 4. Soga S., et al. (1998) J.Biol.Chem. 273: 822. 5. Oikawa T., et al. (1993) Eur.J.Pharmacol. 241: 221. 6. Roe S.M. et al. (1999) J.Med.Chem. 42: 260.